COMPANY OVERVIEW

Limerick BioPharma is dedicated to the discovery and development of novel small molecule product candidates to address areas of significant unmet medical need. Our intent is to bring forth innovative therapies that have the potential to change treatment paradigms via their enhanced safety and / or efficacy profiles. Limerick is developing novel products that can enhance the safety of existing therapeutic agents or function as innovative stand-alone therapies.

Our lead programs are in the areas of metabolic diseases and solid organ transplantation. In metabolic diseases, our programs are in clinical development for treatment of diabetes and dyslipidemia. For transplant indications, our programs are in clinical development as adjunctive therapy to treat metabolic dysregulation induced by leading immunosuppressants. Beyond these first-generation programs, Limerick has developed a proprietary and cutting-edge discovery platform that can be leveraged for other high-need, high-value areas.

We intend to maximize the value of our product candidates and discovery platform through independent development, licensing and other partnership opportunities.